The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Marshall, C. J. (1995) · Cell · doi:10.1016/0092-8674(95)90401-8 · Cited by 3,906
The GTPase superfamily: conserved structure and molecular mechanism
Bourne, H. R., Sanders, D. A., & McCormick, F. (1991) · Nature · doi:10.1038/349117a0 · Cited by 3,392
Self-citationThe GTPase superfamily: a conserved switch for diverse cell functions
Bourne, H. R., Sanders, D. A., & McCormick, F. (1990) · Nature · doi:10.1038/348125a0 · Cited by 2,333
Self-citationProteins regulating Ras and its relatives
Boguski, M. S., & McCormick, F. (1993) · Nature · doi:10.1038/366643a0 · Cited by 1,901
Self-citationStimulation of p21ras upon T-cell activation
Downward, J., Graves, J. D., Warne, P. H., Rayter, S., & Cantrell, D. A. (1990) · Nature · doi:10.1038/346719a0 · Cited by 860
Tumour predisposition in mice heterozygous for a targeted mutation in Nf1
Jacks, T., Shih, T. S., Schmitt, E. M., Bronson, R. T., Bernards, A., & Weinberg, R. A. (1994) · Nature Genetics · doi:10.1038/ng0794-353 · Cited by 778
Self-citationMicroinjection of the ras oncogene protein into PC12 cells induces morphological differentiation
Bar-Sagi, D., & Feramisco, J. R. (1985) · Cell · doi:10.1016/0092-8674(85)90280-6 · Cited by 725
Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients
Basu, T. N., Gutmann, D. H., Fletcher, J. A., Glover, T. W., Collins, F. S., & Downward, J. (1992) · Nature · doi:10.1038/356713a0 · Cited by 668
Brannan, C. I., Perkins, A. S., Vogel, K. S., Ratner, N., Nordlund, M. L., Reid, S. W., Buchberg, A. M., Jenkins, N. A., Parada, L. F., & Copeland, N. G. (1994) · Genes & Development · doi:10.1101/gad.8.9.1019 · Cited by 641
DeClue, J. E., Papageorge, A. G., Fletcher, J. A., Diehl, S. R., Ratner, N., Vass, W. C., & Lowy, D. R. (1992) · Cell · doi:10.1016/0092-8674(92)90407-4 · Cited by 580
Research works printed but not linked: 2
- Riccardi, V.M. & Eichner, J.E. Neurofibromatosis (Johns Hopkins University Press, Baltimore- USA, 1986).
- Kaneko, Y. et al. Chromosome patterns in juvenile chronic myelogenous leukemia, myelodysplastic syndrome, and acute leukemia associated with neurofibromatosis. Leukemia 3, 36–41 (1989).
Cited by
Tartaglia, M., Niemeyer, C. M., Fragale, A., Song, X., Buechner, J., Jung, A., Hählen, K., Hasle, H., Licht, J. D., & Gelb, B. D. (2003) · Nature Genetics · doi:10.1038/ng1156 · Cited by 1,033
Ras in Cancer and Developmental Diseases
Fernandez-Medarde, A., & Santos, E. (2011) · Genes & Cancer · doi:10.1177/1947601911411084 · Cited by 897
Transcription Factors, Normal Myeloid Development, and Leukemia
Tenen, D. G., Hromas, R., Licht, J. D., & Zhang, D.-E. (1997) · Blood · doi:10.1182/blood.v90.2.489 · Cited by 735
Germline KRAS mutations cause Noonan syndrome
Schubbert, S., Zenker, M., Rowe, S. L., Böll, S., Klein, C., Bollag, G., van der Burgt, I., Musante, L., Kalscheuer, V., Wehner, L.-E., et al. (2006) · Nature Genetics · doi:10.1038/ng1748 · Cited by 730
Self-citationZhu, Y., Romero, M. I., Ghosh, P., Ye, Z., Charnay, P., Rushing, E. J., Marth, J. D., & Parada, L. F. (2001) · Genes & Development · doi:10.1101/gad.862101 · Cited by 604
NF1 Tumor Suppressor Gene Function
Cichowski, K., & Jacks, T. (2001) · Cell · doi:10.1016/s0092-8674(01)00245-8 · Cited by 601
Self-citationThe NF1 tumor suppressor critically regulates TSC2 and mTOR
Johannessen, C. M., Reczek, E. E., James, M. F., Brems, H., Legius, E., & Cichowski, K. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503224102 · Cited by 601
Optic pathway gliomas in neurofibromatosis‐1: Controversies and recommendations
Listernick, R., Ferner, R. E., Liu, G. T., & Gutmann, D. H. (2007) · Annals of Neurology · doi:10.1002/ana.21107 · Cited by 576
A negative feedback signaling network underlies oncogene-induced senescence
Courtois-Cox, S., Genther Williams, S. M., Reczek, E. E., Johnson, B. W., McGillicuddy, L. T., Johannessen, C. M., Hollstein, P. E., MacCollin, M., & Cichowski, K. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.10.003 · Cited by 501
A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor
Ratner, N., & Miller, S. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3911 · Cited by 493
Mouse Models of Tumor Development in Neurofibromatosis Type 1
Cichowski, K., Shih, T. S., Schmitt, E., Santiago, S., Reilly, K., McLaughlin, M. E., Bronson, R. T., & Jacks, T. (1999) · Science · doi:10.1126/science.286.5447.2172 · Cited by 467
Self-citationHofmann, M. H., Gmachl, M., Ramharter, J., Savarese, F., Gerlach, D., Marszalek, J. R., Sanderson, M. P., Kessler, D., Trapani, F., Arnhof, H., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0142 · Cited by 444
Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis
Loh, M. L. (2004) · Blood · doi:10.1182/blood-2003-09-3287 · Cited by 427
Niemeyer, C. M., Aricò, M., Basso, G., Biondi, A., Rajnoldi, A. C., Creutzig, U., Haas, O. A., Harbott, J., Hasle, H., Kerndrup, G. B., et al. (1997) · PubMed · doi:10.1182/blood.v89.10.3534 · Cited by 406
The tyrosine phosphatase Shp2 (PTPN11) in cancer
Chan, G., Kalaitzidis, D., & Neel, B. G. (2008) · Cancer and Metastasis Reviews · doi:10.1007/s10555-008-9126-y · Cited by 382
PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase
Chan, R. J., & Feng, G.-S. (2007) · Blood · doi:10.1182/blood-2006-07-028829 · Cited by 371
Roberts, C. W. M., Leroux, M. M., Fleming, M. D., & Orkin, S. H. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00185-x · Cited by 333
Malignancy in Neurofibromatosis Type 1
Korf, B. R. (2000) · The Oncologist · doi:10.1634/theoncologist.5-6-477 · Cited by 328
THE POTENTIAL OF FARNESYLTRANSFERASE INHIBITORS AS CANCER CHEMOTHERAPEUTICS
Gibbs, J. B., & Oliff, A. (1997) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.37.1.143 · Cited by 324
Bajenaru, M. L., Zhu, Y., Hedrick, N. M., Donahoe, J., Parada, L. F., & Gutmann, D. H. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.14.5100-5113.2002 · Cited by 322
MLL3 Is a Haploinsufficient 7q Tumor Suppressor in Acute Myeloid Leukemia
Chen, C., Liu, Y., Rappaport, A. R., Kitzing, T., Schultz, N., Zhao, Z., Shroff, A. S., Dickins, R. A., Vakoc, C. R., Bradner, J. E., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.03.016 · Cited by 311
Self-citationDasgupta, B., Yi, Y., Chen, D. Y., Weber, J. D., & Gutmann, D. H. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4058 · Cited by 308
Reuter, C. W. M., Morgan, M. A., & Bergmann, L. (2000) · Blood · doi:10.1182/blood.v96.5.1655 · Cited by 300
Braun, B. S., Tuveson, D. A., Kong, N., Le, D. T., Kogan, S. C., Rozmus, J., Le Beau, M. M., Jacks, T. E., & Shannon, K. M. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307203101 · Cited by 299
Self-citationSide, L., Taylor, B., Cayouette, M., Conner, E., Thompson, P., Luce, M., & Shannon, K. (1997) · New England Journal of Medicine · doi:10.1056/nejm199706123362404 · Cited by 295
Self-citationCalcineurin signaling and NFAT activation in cardiovascular and skeletal muscle development
Schulz, R. A., & Yutzey, K. E. (2004) · Developmental Biology · doi:10.1016/j.ydbio.2003.10.008 · Cited by 290
Mohi, M. G., Williams, I. R., Dearolf, C. R., Chan, G., Kutok, J. L., Cohen, S., Morgan, K., Boulton, C., Shigematsu, H., Keilhack, H., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.01.010 · Cited by 277
The role of Shp2 (PTPN11) in cancer
Mohi, M. G., & Neel, B. G. (2007) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2006.12.011 · Cited by 274
Chan, I. T., Kutok, J. L., Williams, I. R., Cohen, S., Kelly, L., Shigematsu, H., Johnson, L., Akashi, K., Tuveson, D. A., Jacks, T., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci20476 · Cited by 270
“KM + 18–99 (36) 11–47 (26) 434–2,081 (1,194) 205–2,300 (677) 882–2,290 (1,703) MPD n = 22 n = 22 n = 22 n = 25 n = 25”
BackgroundSelf-citationNMR-based functional profiling of RASopathies and oncogenic RAS mutations
Smith, M. J., Neel, B. G., & Ikura, M. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1218173110 · Cited by 257
“We were able to detect NF1-deficiency in tumor-derived cells, which had previously required meticulous radio-labeling experiments (15, 36).”
BackgroundMethodRescue of a Drosophila NF1 Mutant Phenotype by Protein Kinase A
The, I., Hannigan, G. E., Cowley, G. S., Reginald, S., Zhong, Y., Gusella, J. F., Hariharan, I. K., & Bernards, A. (1997) · Science · doi:10.1126/science.276.5313.791 · Cited by 255
Protein tyrosine phosphatase SHP-2: A proto-oncogene product that promotes Ras activation
Matozaki, T., Murata, Y., Saito, Y., Okazawa, H., & Ohnishi, H. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01257.x · Cited by 240
Molecular and Clinical Aspects of Drug-induced Gingival Overgrowth
Trackman, P. C., & Kantarci, A. (2015) · Journal of Dental Research · doi:10.1177/0022034515571265 · Cited by 155
Zhang, Y.-Y., Vik, T. A., Ryder, J. W., Srour, E. F., Jacks, T., Shannon, K., & Wade Clapp, D. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.11.1893 · Cited by 150
“Ligand-induced activation of many hematopoietic growth factor receptors transiently increases the Ras-GTP levels, which in turn influences the survival, proliferation, and differentiation of myeloid-lineage cells.”
InfluentialSelf-citationInherited predispositions and hyperactive Ras in myeloid leukemogenesis
Lauchle, J. O., Braun, B. S., Loh, M. L., & Shannon, K. (2006) · Pediatric Blood & Cancer · doi:10.1002/pbc.20644 · Cited by 94
Self-citationRAS and beyond: the many faces of the neurofibromatosis type 1 protein
Anastasaki, C., Orozco, P., & Gutmann, D. H. (2022) · Disease Models & Mechanisms · doi:10.1242/dmm.049362 · Cited by 86
Huang, W., Horvath, E., & Eklund, E. A. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m607760200 · Cited by 58
Sudhan, D. R., Guerrero-Zotano, A., Won, H., González Ericsson, P., Servetto, A., Huerta-Rosario, M., Ye, D., Lee, K.-M., Formisano, L., Guo, Y., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2019.12.013 · Cited by 49
“NF1 acts as a tumor suppressor by promoting GTP hydrolysis of RAS and inactivating RAS signaling (Bollag et al., 1996).”
BackgroundZhu, C., Saberwal, G., Lu, Y., Platanias, L. C., & Eklund, E. A. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m405736200 · Cited by 45
Huang, W., Saberwal, G., Horvath, E., Zhu, C., Lindsey, S., & Eklund, E. A. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.00036-06 · Cited by 41
“Specifically, Nf1 Ras-GAP activity antagonizes granulocyte-macrophage colony-stimulating factor (GM-CSF)-, stem cell factor (SCF)-, or macrophage colony-stimulating factor (M-CSF)-induced Ras activation in myeloid cells (2, 4 , 34).”
BackgroundLu, D., Nounou, R., Beran, M., Estey, E., Manshouri, T., Kantarjian, H., Keating, M. J., & Albitar, M. (2003) · Cancer · doi:10.1002/cncr.11037 · Cited by 23
A microglia clonal inflammatory disorder in Alzheimer’s disease
Vicario, R., Fragkogianni, S., Weber, L., Lazarov, T., Hu, Y., Hayashi, S. Y., Craddock, B., Socci, N. D., Alberdi, A., Baako, A., et al. (2025) · eLife · doi:10.7554/elife.96519.3 · Cited by 21
Vara, N., Liu, Y., Yan, Y., Lensing, S. Y., Colorado, N., Robinson, D., Zhang, J., Zhang, X., Peterson, E. A., Baltz, N. J., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020002326 · Cited by 5
Metadata
- Authors
- Bollag, G., Clapp, D. W., Shih, S., Adler, F., Zhang, Y. Y., Thompson, P., Lange, B. J., Freedman, M. H., McCormick, F., Jacks, T., & Shannon, K.
- Venue
- Nature Genetics
- Published
- 1996-02-01
- Volume
- 12
- Issue
- 2
- Pages
- 144-148
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W2073998405
- Cited by
- 589
- References
- 43
- FWCI
- 19.47
- Type
- journal article
- Language
- en
- Update notices
- correction (1996-04-01)
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.